Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development

REFERENCES

• Adams, J. M., A. W. Harris, C. A. Pinkert, L. M. Corcoran, W. S. Alexander, S. Cory, R. D. Palmiter, and R. L. Brinster. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533–538.
   PubMed Web of Science ®Google Scholar
• Alt, J. R., T. C. Greiner, J. L. Cleveland, and C. M. Eischen. 2003. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J. 22:1442–1450.
   PubMed Web of Science ®Google Scholar
• Bond, G. L., W. Hu, E. E. Bond, H. Robins, S. G. Lutzker, N. C. Arva, J. Bargonetti, F. Barte, H. Taubert, P. Wuerl, K. Onel, L. Yip, S. J. Hwang, L. C. Strong, G. Lozano, and A. J. Levine. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602.
   PubMed Web of Science ®Google Scholar
• Bond, G. L., W. Hu, and A. Levine. 2005. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 65:5481–5484.
   PubMed Web of Science ®Google Scholar
• Danovi, D., E. Meulmeester, D. Pasini, D. Migliorini, M. Capra, R. Frenk, P. de Graaf, S. Francoz, P. Gasparini, A. Gobbi, K. Helin, P. G. Pelicci, A. G. Jochemsen, and J.-C. Marine. 2004. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell. Biol. 24:5835–5843.
   PubMed Web of Science ®Google Scholar
• Dornan, D., S. Bheddah, K. Newton, W. Ince, G. D. Frantz, P. Dowd, H. Koeppen, V. M. Dixit, and D. M. French. 2004. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 64:7226–7230.
   PubMed Web of Science ®Google Scholar
• Eischen, C. M., J. D. Weber, M. F. Roussel, C. J. Sherr, and J. L. Cleveland. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13:2658–2669.
   PubMed Web of Science ®Google Scholar
• Evans, S. C., M. Viswanathan, J. D. Grier, M. Narayana, A. K. El-Naggar, and G. Lozano. 2001. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20:4041–4049.
   PubMed Web of Science ®Google Scholar
• Finch, R. A., D. B. Donoviel, D. Potter, M. Shi, A. Fan, D. D. Freed, C. Y. Wang, B. P. Zambrowicz, R. Ramirez-Solis, A. T. Sands, and N. Zhang. 2002. mdmx is a negative regulator of p53 activity in vivo. Cancer Res. 62:3221–3225.
   PubMed Web of Science ®Google Scholar
• Greenblatt, M. S., W. P. Bennett, M. Hollstein, and C. C. Harris. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855–4878.
   PubMed Web of Science ®Google Scholar
• Grier, J. D., S. Xiong, A. C. Elizondo-Fraire, J. M. Parant, and G. Lozano. 2006. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol. Cell. Biol. 26:192–198.
   PubMed Web of Science ®Google Scholar
• Jacks, T., L. Remington, B. O. Williams, E. M. Schmitt, S. Halachmi, R. T. Bronson, and R. A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1–7.
   PubMed Web of Science ®Google Scholar
• Jones, S. N., A. E. Roe, L. A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206–208.
   PubMed Web of Science ®Google Scholar
• Leng, R. P., Y. Lin, W. Ma, H. Wu, B. Lemmers, S. Chung, J. M. Parant, G. Lozano, R. Hakem, and S. Benchimol. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112:779–791.
   PubMed Web of Science ®Google Scholar
• Lewis, P. M., A. Gritli-Linde, R. Smeyne, A. Kottmann, and A. P. McMahon. 2004. Sonic hedgehog signaling is required for expansion of granule neuron precursors and patterning of the mouse cerebellum. Dev. Biol. 270:393–410.
   PubMed Web of Science ®Google Scholar
• McDonnell, T. J., R. Montes de Oca Luna, S. Cho, L. L. Amelse, A. Chavez-Reyes, and G. Lozano. 1999. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J. Pathol. 188:322–328.
   PubMedGoogle Scholar
• Mendrysa, S. M., M. K. McElwee, J. Michalowski, K. A. O'Leary, K. M. Young, and M. E. Perry. 2003. Mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell. Biol. 23:462–472.
   PubMed Web of Science ®Google Scholar
• Mendrysa, S. M., K. A. O'Leary, M. K. McElwee, J. Michalowski, R. N. Eisenman, D. A. Powell, and M. E. Perry. 2006. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 20:16–21.
   PubMed Web of Science ®Google Scholar
• Migliorini, D., E. Lazzerini Denchi, D. Danovi, A. Jochemsen, M. Capillo, A. Gobbi, K. Helin, P. G. Pelicci, and J. C. Marine. 2002. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol. 22:5527–5538.
   PubMed Web of Science ®Google Scholar
• Montes de Oca Luna, R., D. S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203–206.
   PubMed Web of Science ®Google Scholar
• Parant, J., A. Chavez-Reyes, N. A. Little, W. Yan, V. Reinke, A. G. Jochemsen, and G. Lozano. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29:92–95.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J. 2001. Cell cycle control and cancer. Harvey Lect. 96:73–92.
   Google Scholar
• Vogelstein, B., and K. W. Kinzler. 2001. Achilles' heel of cancer? Nature 412:865–866.
   PubMedGoogle Scholar